Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.
Sosei Heptares announced on Dec. 16, 2022 that it has entered a drug discovery collaboration with Eli Lilly with the goal to discover, develop, and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases.
The agreement will use Sosei Heptares’ StaR technology and structure-based drug design platform and Lilly’s extensive drug development and commercialization expertise as well as its therapeutic area expertise in diabetes and metabolic diseases. Sosei Heptares is eligible to receive $37 million upfront in cash and commercial milestone payments totaling up to $694 million, plus tiered royalties.
“This new agreement with Lilly further reinforces our position as a global partner of choice for GPCR-focused drug discovery targeting major diseases where patients remain in need of new and effective therapies,” said Matt Barnes, head of UK research & development, Sosei Heptares, in a company press release. “We provide a highly attractive approach that is recognized by many of the world’s leading biopharmaceutical companies and are delighted to add Lilly to that list. Lilly is a recognized world leader in diabetes and metabolic diseases, and we look forward to a collaboration that brings together our respective and complementary expertise with the goal of identifying and developing novel candidates to advance in these important areas of unmet need.”
Source: Sosei Heptares
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.